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Abstract 
Background: Post-transcriptional regulation by heterogeneous ribonucleoproteins (hnRNPs) is an important regula-
tory paradigm in cancer development. Our proteomic analysis revealed hnRNPD overexpression in oral dysplasia as 
compared with normal mucosa; its role in oral carcinogenesis remains unknown. Here in we determined the hnRNPD 
associated protein networks and its clinical significance in oral squamous cell carcinoma (OSCC).
Methods: Immunoprecipitation (IP) followed by tandem mass spectrometry was used to identify the binding part-
ners of hnRNPD in oral cancer cell lines. Ingenuity pathway analysis (IPA) was carried out to unravel the protein inter-
action networks associated with hnRNPD and key interactions were confirmed by co-IP-western blotting. hnRNPD 
expression was analyzed in 183 OSCCs, 44 oral dysplasia and 106 normal tissues using immunohistochemistry (IHC) 
and correlated with clinico-pathological parameters and follow up data over a period of 91 months. Kaplan–Meier 
survival and Cox-multivariate-regression analyses were used to evaluate the prognostic significance of hnRNPD in 
OSCC.
Results: We identified 345 binding partners of hnRNPD in oral cancer cells. IPA unraveled novel protein–protein inter-
action networks associated with hnRNPD and suggested its involvement in multiple cellular processes: DNA repair, 
replication, chromatin remodeling, cellular proliferation, RNA splicing and stability, thereby directing the fate of oral 
cancer cells. Protein–protein interactions of hnRNPD with 14-3-3ζ, hnRNPK and S100A9 were confirmed using co-IP-
western blotting. IHC analysis showed significant overexpression of nuclear hnRNPD in oral dysplasia [p = 0.001, Odds 
ratio (OR) = 5.1, 95 % CI = 2.1–11.1) and OSCCs (p = 0.001, OR = 8.1, 95 % CI = 4.5–14.4) in comparison with normal 
mucosa. OSCC patients showing nuclear hnRNPD overexpression had significantly reduced recurrence free survival 
[p = 0.026, Hazard ratio = 1.95, 95 % CI = 1.0–3.5] by Kaplan–Meier survival and Cox-multivariate-regression analyses 
and has potential to define a high-risk subgroup among OSCC patients with nodal negative disease.
Conclusions: Our findings suggest novel functions of hnRNPD in cellular proliferation and survival, besides RNA 
splicing and stability in oral cancer. Association of nuclear hnRNPD with poor prognosis in OSCC patients taken 
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Background
Post-transcriptional regulation of mRNA stability and 
translation by RNA binding proteins (RBPs) is a key deter-
minant of gene expression [1–3]. These RNA–protein 
interactions dictate the ultimate fate of the transcripts and 
are emerging as an important regulatory paradigm in can-
cer development [3, 4]. The mRNA decay kinetics is largely 
controlled by presence of specific cis-acting sequence and/
or structural determinants within each transcript [5, 6]. 
About 16 % of all human protein coding genes are encoded 
by mRNAs that contain an adenylate-uridylate (AU)-rich 
element [ARE] motif within their 3′UTR [1, 2, 5, 6]. AU-
rich RNA-binding factor (AUF1)/heterogeneous nuclear 
ribonucleoprotein D (hnRNPD) is an ARE-binding pro-
tein which regulates the mRNA stability of many genes 
involved in cell cycle, proliferation, survival, senescence 
and stress response [1, 2, 3, 4, 5, 7, 8, 9, 10, 11]. This protein 
harbors two RNA-binding domains arranged in tandem 
and a glycine-rich region in the C-terminus (2x RBD-
Gly) and regulates the cellular half-life of many mRNAs 
by directly interacting with AREs in their 3′untrans-
lated region [12–15]. Overexpression of hnRNPD in vivo 
resulted in deregulation of mRNAs including c-myc, 
c-jun, c-fos, and tumor necrosis factor-α (TNF-α) which 
promote tumorigenesis suggesting an oncogenic role of 
hnRNPD [1, 2, 3, 16, 17]. Increased hnRNPD expression 
also reduced the cell cycle checkpoint regulators p21 and 
p16Ink4a, a critical mediator of senescence [10, 18, 19]. 
Nuclear hnRNPD has been shown to activate the tran-
scription promoter for telomerase catalytic subunit Tert, 
and links maintenance of telomere length and normal 
aging to attenuation of inflammatory cytokine expression 
and inhibition of cellular senescence [20].
Head and neck squamous cell carcinoma (HNSCC) 
ranks as the sixth leading cause of cancer related deaths 
worldwide [21]. HNSCCs often show heterogeneous 
pathologic and clinical features and diverse outcome 
[22, 23]. HNSCC is among the most morbid human 
malignancies and the quality of life in survivors is poor. 
Moreover, HNSCC patients often have recurrence of 
the tumor at the same site, or develop second primary 
tumors, frequently attributed to field cancerization [8]. 
Oral squamous cell carcinomas (OSCCs) comprise a large 
proportion of HNSCCs. The lack of clinically proven bio-
markers limits therapeutic decisions to be solely based 
on tumor site and staging. However, tumors with simi-
lar clinical features can differ in disease outcome [24]. 
A better understanding of the molecular pathogenesis 
of OSCC is urgently needed for rigorous disease man-
agement. The development of OSCCs is often preceded 
by clinically distinct oral lesions such as leukoplakia or 
erythroplakia with histological evidence of squamous cell 
hyperplasia or dysplasia; on an average about one percent 
of these lesions transform to cancer annually. The oral 
lesions with histologically proven dysplasia are called Oral 
premalignant or potentially malignant lesions (OPLs). 
Identification of OPLs at high risk of progression to can-
cer is a high priority to enable early intervention, prior to 
development of frank malignancy for more effective dis-
ease management and improve the quality of life in sur-
vivors [25]. We reported overexpression of hnRNPD in 
human oral premalignant lesions by proteomic analysis 
[26]. In this study, interactome analysis was undertaken 
to gain an insight into hnRNPD associated protein–pro-
tein networks, by identifying its binding partners in oral 
cancer cells using immunoprecipitation followed by liquid 
chromatography—tandem mass spectrometry (LC–MS/
MS). Bioinformatic analysis based cellular networks and 
pathways were identified and protein–protein interac-
tions were confirmed using oral cancer cells. Further, we 
also determined the significance of hnRNPD overexpres-
sion in clinical specimens of oral dysplasia and cancer and 
correlated with disease outcome.
Methods
Cell culture
Oral squamous cell carcinoma (OSCC) cell line, SCC4 
was obtained from American Type Culture Collection 
(ATCC), HSC2 (JCRB0622) from Health Science Research 
Resources Bank, Japan (HSRRB); Tu167 and MDA1986 
were a kind gift from MD Anderson Cancer Centre (Hou-
ston, Texas). All cell lines were characterized using short 
tandem repeat polymorphism (STR) analysis. OSCC cells 
were grown in monolayer cultures in Dulbecco’s modified 
eagle medium (DMEM) (Sigma Aldrich, St. Louis, MO) 
supplemented with 10 % fetal bovine serum (FBS) (Sigma), 
1 mM l-glutamine, 100 μg/ml streptomycin and 100 U/ml 
penicillin in a humidified incubator (5 % carbon-dioxide, 
95 % air) at 37 °C as described previously [26, 27].
Patients, tissue specimens, clinicopathological data 
and follow‑up
The Institutional Human Ethics Committee of All India 
Institute of Medical Sciences (AIIMS), New Delhi, 
together with its associated protein networks in oral cancer warrant future studies designed to explore its potential as 
a plausible novel target for molecular therapeutics.
Keywords: hnRNPD/AUF1, Dysplasia, Oral cancer, Prognosis, mRNA stability, Interactome
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India, approved this study prior to its commencement 
(NO.IESC/T-261/03.06.2011). Tissue specimens were 
obtained from patients with oral dysplasia (n  =  44) as 
revealed by H&E staining from Department of Otorhi-
nolaryngology, All India Institute of Medical Sciences 
(AIIMS) and from 183 OSCC patients undergoing cura-
tive cancer surgery during the period 2002–2008, after 
obtaining patients’ consent, while 106 non-malignant 
oral tissues with histological evidence of normal epithe-
lium constituted the normal group. Patient demographic, 
clinical, and pathological data were recorded in a pre-
designed performa [27].
Of the 183 OSCCs, 144 cases could be followed-up 
in the head-and-neck cancer follow-up clinic at regular 
time intervals up to a maximum period of 91 months as 
of May, 2013. The patients were revisited clinically on a 
regular basis and the time to recurrence was recorded. 
Of these 144 OSCC patients, loco-regional relapse was 
observed in 60 cases (41.7  %), while 14 patients died 
(9.7 %) as determined from follow-up reports. If a patient 
died, the survival time was censored at the time of death; 
the medical history, clinical examination, and radiologi-
cal evaluation were used to determine whether the death 
had resulted from recurrent cancer (relapsing patients) or 
from any other causes. Recurrence-free survivors (RFS) 
were defined as patients free from clinical and radiologi-
cal evidence of local or regional recurrence or death at 
the time of the last follow-up.
Real time‑PCR analysis of hnRNPD mRNA levels in OSCCs 
and normal oral mucosa
For this study, hnRNPD mRNA level was determined 
in 12 paired tumor and normal tissue samples. Total 
RNA was extracted from a small portion of the biop-
sies OSCCs and normal oral tissues with Trizol reagent 
(Invitrogen, CA) according to the manufacturer’s pro-
tocol. The quality of the isolated RNA was tested by its 
optical density (260/280 ratio is 2.0). The expression of 
hnRNPD was quantified by real-time PCR (RT-qPCR). 
Total RNA (1 μg) was reverse-transcribed using Reverse 
transcriptase (Thermo Scientific, Waltham, MA, USA) 
using oligo-dT primers according to the manufacturer’s 
instructions. Real-time PCR reactions were performed 
and quantified by Maxima SYBR Green (Thermo Scien-
tific, Waltham, MA, USA) using CFX96 Touch™ Real-
Time PCR Detection System (BioRad, Hercules, CA, 
USA) using the ribosomal 18S gene as an internal control 
for normalisation. All assays were performed in tripli-
cate in a 20 μl two-step reaction. The specificity of the 
amplified PCR products was assessed by melting curve 
analysis and agarose gel electrophoresis of a small aliquot 
of the reaction followed by staining with ethidium bro-
mide. The efficiency of the qPCR reaction was measured 
in separate assays using cDNA obtained from total RNA 
of SCC4, HSC2, TU167 and MDA1986 oral cancer cell 
lines. The primer sequences are shown: hnRNPD–Sense: 
GCCTTTCTCCAGATACACCTGAAG; Antisense: CT 
TATTGGTCTTGTTGTCCA TGGG and 18S riboso-
mal–Sense: GTAACCCGTTGAACCCCATT, Antisense: 
CCA TCCAATCGGTAGTAGCG.
Immunoblotting
Whole-cell lysates were prepared from OSCC cells 
(SCC4/HSC2/Tu167/MDA1986), oral normal tissues 
(n = 4), dysplasia (n = 2), and OSCC (n = 8) by homog-
enization in RIPA lysis buffer [26, 27]. Equal amounts of 
proteins (60  μg/lane) were resolved and electro-trans-
ferred onto polyvinylidene-difluoride (PVDF) mem-
brane. After blocking blots were incubated with rabbit 
polyclonal hnRNPD antibody at 4  °C overnight. β-actin 
served as a control for equal protein loading in each lane. 
Membranes were incubated with their respective HRP-
conjugated secondary antibody (DAKO Cytomation, 
Glostrup, Denmark), diluted at an appropriate dilution 
in 1 % BSA, for 2 h at room temperature. Protein bands 
were detected by the enhanced chemiluminescence 
method (ECL, Pierce, IL) on XO-MAT film.
Immunoprecipitation
Oral cancer cells (SCC4/MDA1986) were lyzed in IP-lysis 
buffer as described [20]. Lysates were pre-cleared with 
Protein A-Sepharose (GE Healthcare Biosciences, Swe-
den), and immunecomplexes were obtained by incuba-
tion with polyclonal hnRNPD antibody and pulled down 
by incubating with Protein A-Sepharose. In negative 
controls, only Protein A Sepharose beads were added to 
eliminate proteins that bind non-specifically to the beads. 
Immunecomplexes were resolved on 10  % SDS-PAGE, 
stained with gel code blue and analyzed by reverse phase 
(RP)-liquid chromatography mass spectrometry (LC–
MS/MS) as described [28, 29].
Reverse phase (RP)‑liquid chromatography mass 
spectrometry (LC–MS/MS)
The proteins bands were excised from gels and digested 
with trypsin as described [28, 29]. The digested pep-
tides from each band were analyzed in duplicates using a 
Nanobore LC system (LC Packings, Amsterdam, Nether-
lands) and a QSTAR Pulsar mass spectrometer (Applied 
Biosystems/MDS SCIEX, Foster City, CA) in positive 
ion mode, externally calibrated with bovine serum albu-
min tryptic peptides [28, 29]. MS data were acquired in 
information-dependent acquisition (IDA) mode using 
Analyst QS 1.1 software (Applied Biosystems/MDS 
SCIEX). The LC–MS/MS was performed using a 1  s 
TOF–MS survey scan from 400 to 1500 Da, followed by 
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four, 2  s product-ion scans, from 80 to 2000  Da, of the 
five most-abundant peaks. The collision energy (CE) was 
automatically controlled by the IDA CE parameter script. 
Switching criteria were set for ions with m/z ≥ 400 and 
<1500, charge states of +2 to +4, and abundances of ≥10 
counts. Former target ions were excluded for 30  s, and 
ions within a 100-ppm window were ignored. To mini-
mize redundancy in subsequent iterations, precursor ion 
exclusion (PIE) list was added to LC–MS/MS method as 
described earlier [28, 29].
Identification of binding partners
LC–MS/MS data of each sample was used to identify 
proteins by searching a concatenated Swissprot/Panther 
database of 66082 distinct human protein entries (version 
June 2, 2010). The database was searched using Protein-
pilot software, version 2.0.1 (AB SCIEX, Foster City), and 
the Paragon algorithm [30]. Protein identification was 
performed at a confidence threshold of 95 % (Proteinpilot 
Unused score ≥1.3) with methyl methanethiosulfonate 
(MMTS) selected as cysteine modification, and with 
the search option ‘emphasis on biological modifications’ 
checked. Peptide and protein summaries were generated. 
Only proteins identified with local false discovery rate 
(FDR) equal to, or less than, 5 % were considered for fur-
ther analysis [28, 29]. Redundant proteins and peptides, 
proteins identified in reverse sequence and in negative 
controls (i.e. beads only) were removed from the list of 
identified proteins.
Confocal laser scan microscopy (CLSM)
For CLSM, 5 × 104 OSCC cells (SCC4/MDA1986) were 
plated on cover slips and grown for 24 h fixed in acetone: 
methanol mixture (1:1) at −20 °C for 20 min. [28]. Cells 
were permeabilized with PBS-0.1 % Tween 20, non-spe-
cific binding blocked with 5  % BSA for 1  h; cells were 
incubated with rabbit polyclonal hnRNPD (ab50692)/
mouse monoclonal hnRNPK (ab23644, Abcam, CA) 
antibody at 4  °C overnight. Expression of proteins was 
determined using fluorescein isothiocyanate (FITC)/
TRITC-labeled secondary antibodies (DAKO Cytoma-
tion, Denmark) [27].
Immunohistochemistry of hnRNPD, hnRNPK and 14‑3‑3ζ 
in oral tissues and scoring
Paraffin-embedded tissue sections were deparaffi-
nized, antigen was retrieved, endogenous peroxidase 
activity was quenched with hydrogen peroxide (0.3  % 
v/v) and non-specific binding blocked with 1  % bovine 
serum albumin (BSA). The slides were incubated with 
either rabbit polyclonal anti-hnRNPD antibody (1  μg/
ml, ab50692, Abcam, CA) or mouse monoclonal anti-
hnRNPK antibody (ab23644) or rabbit polyclonal 14-3-3ζ 
antibody (sc-1019) for 16 h at 4 °C. The primary antibody 
was detected using the Dako Envision kit (Dako CYTO-
MATION, Glostrup, Denmark) with diaminobenzidine 
as the chromogen and counterstained with hematoxylin 
[26, 27]. The sections were evaluated by light microscopy 
and scored using a semi-quantitative scoring system for 
both staining intensity (nuclear/cytoplasmic) and per-
centage positivity as described earlier [26, 27]. The tissue 
sections were scored based on the % of immunostained 
cells as: 0–10 % = 0; >10–30 % = 1; >30–50 % = 2; >50–
70 % = 3 and >70–100 % = 4. Sections were also scored 
semi-quantitatively on the basis of staining intensity 
as negative  =  0; mild  =  1; moderate  =  2; intense  =  3. 
Finally, a total score was obtained by adding the score of 
percentage positivity and intensity giving a score range 
from 0 to 7. IHC score thus obtained for different pro-
teins were subjected to statistical analysis.
Statistical analysis
The immunohistochemical data were subjected to sta-
tistical analyses using the SPSS 20.0 software (Chicago, 
IL, USA). Sensitivity and specificity was calculated 
using receiver operating characteristic (ROC) analyses. 
Based on sensitivity and specificity values a cut-off ≥4 
was defined as positive criterion for hnRNPD (nuclear/
cytoplasmic). The relationships between hnRNPD and 
clinicopathological parameters were tested using Chi 
Square and Fischer’s exact test. Two-sided p-values were 
calculated and p < 0.05 was considered to be significant. 
Similarly, positive predictive value (PPV) and negative 
predictive value (NPV) were calculated for hnRNPD 
overexpression in oral lesions and OSCCs in comparison 
with normal oral mucosa. The correlation of hnRNPD 
staining with patient survival was evaluated using life 
tables constructed from survival data with Kaplan–Meier 
plots and Cox regression multivariate analysis. In order 
to confirm the association among hnRNPD, hnRNPK 
and 14-3-3ζ overexpression in clinical specimens of 
OSCCs, we performed Kappa analysis to determine the 
agreement of association between these proteins using 
their IHC scores. One of the most important features of 
the Kappa statistical analysis is its ability to measure the 
degree of agreement or reliability of agreement [26–28].
Results
Expression of hnRNPD in oral cancer cells and tissues
Real time PCR and Western blotting were performed to 
determine the expression of hnRNPD transcripts and 
protein expression levels respectively in oral cancer cells 
(SCC4, HSC2, Tu167 and MDA1986), OSCCs and nor-
mal oral mucosa tissues. Real time PCR analysis revealed 
increased hnRNPD transcript levels in oral cancer cell 
lines (SCC4, HSC2, Tu167 and MDA1986) and OSCC 
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tissue samples in comparison with normal oral epithe-
lium (Fig. 1a, p = 0.007). These data were further verified 
using Western blot analysis.
Western blot analysis showed a single intense band of 
37 kDa in all the oral cancer cell lines tested (SCC4, HSC2, 
Tu167 and MDA167, Fig. 1b), dysplasia (d1, d2) and OSCCs 
(t1–t8) demonstrating the presence of only p37/AUF1 iso-
form of hnRNPD. Faint or no expression of hnRNPD was 
observed in normal oral tissues (n1–n4), while an intense 
band was observed in OSCCs, thus confirming hnRNPD 
protein overexpression in OSCCs (Fig. 1b).
Identification of binding partners of hnRNPD in OSCC cells
To gain an insight into the role of hnRNPD in OSCCs, 
we identified its binding partners in oral cancer cell lines 
(SCC4 and MDA1986). Immunoprecipitates obtained 
from SCC4 and MDA1986 cells using hnRNPD specific 
antibody were separated on 10  % SDS-PAGE, stained 
with gel-code blue, 35 protein bands were excised from 
the immunoprecipated sample and from the mock 
treated sample, digested with trypsin and subjected to 
RP-LC–MS/MS analysis for identification of proteins 
(Additional file  1: Figure S1A, Additional file  2: Figure 
S1B). Our novel approach using multiple iterations and 
development of precursor ion exclusion (PIE) list for 
protein identification revealed 345 binding partners of 
hnRNPD in oral cancer cell lines (Additional file 3: Table 
S1). Our approach revealed interactions of hnRNPD with 
17 members of hnRNP family including hnRNPA2/B1, 
hnRNPK, hnRNPU, hnRNPG suggesting that hnRNPD 
Fig. 1 Analysis of hnRNPD expression in oral tissues. a Quantitative real time PCR (qPCR) analysis of hnRNPD transcripts in oral cancer cells, OSCCs 
and normal tissues. i Analysis of hnRNPD mRNA levels in oral cancer cell line. Total cellular RNA from various oral cancer cell lines (SCC-4, HSC-2, 
Tu-167, MDA-1986) were isolated, reverse transcribed and subjected to real time PCR analysis using specific hnRNPD primers. Simultaneously real 
time PCR for 18S ribosomal RNA was performed and served as an internal control for normalization. After real time PCR the 2−Δct value of hnRNPD 
mRNA obtained in SCC-4 cells was assigned a value of 1 and the fold increase in other cell lines was calculated relative to this. Histogram shows the 
relative abundance of hnRNPD transcripts in SCC4, HSC2, Tu167 and MDA1986. ii Expression of hnRNPD transcripts in 12 random OSCCs samples 
and their paired normal tissues. Total cellular RNA was isolated from OSCCs and their paired normal tissues, reverse transcribed, and subjected 
to real time PCR analysis using specific hnRNPD primers. Parallel real time PCR for 18S ribosomal RNA was performed which served as an internal 
control for normalization of hnRNPD mRNA levels in OSCC and paired normal tissues. After normalization the fold increase in the levels of hnRNPD 
transcripts in each OSCC sample over their respective paired normal tissue was calculated and plotted individually. hnRNPD mRNA levels were 
significantly higher in oral OSCCs patients as compared to their paired normal oral tissue samples (p = 0.007, Mann–Whitney U test). Bar graph data 
is represented by fold changes of OSCCs samples after normalization with paired normal tissue samples. iii A representation of scatter plot after 
normalized 2−Δct values of each OSCCs and paired normal tissue samples. b Western blot analysis. Photomicrograph showing protein expression of 
hnRNPD in (i) oral cancer cell lines (SCC4, HSC2, Tu167 and MDA1986); ii tissue lysates obtained from normal oral mucosa (n1–n4), oral dysplasia (d1, 
d2) and OSCCs (t1–t8). Panel shows increased expression of hnRNPD in dysplasia (d1, d2) and OSCCs (t1–t8) as compared to normal mucosa (n1–
n4). Whole cell lysates prepared from SCC4 cells was used as a positive control. β-actin was used as loading control (lower panel)
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forms heterodimers with its family members (Additional 
file 3: Table S1). hnRNPD also showed interactions with 
proteins involved in short-interfering-RNA (RNAi)-
mediated gene silencing (EIF2C1, EIF2C2, EIF2C3), 
DNA repair (XRCC5, XRCC6), chromatin remodeling 
(SMARCC1, SMARCC2, SMARCB1; histone family of 
proteins including H1, H2A, H2B and H4), tumor pro-
tein 63 (TP63), transcription factors (zinc finger domain 
proteins, ZC3HAV1, ZCCHC8), cell signaling proteins 
(IGFBP, G3BP1, GNB2L1, NCL), nuclear-shuttling pro-
teins (14-3-3ζ), S100A9 (calcium binding protein) and 
several other proteins involved in RNA splicing, sta-
bility and decay (ribosomal proteins 28S, 40S and 60S; 
ATP dependent RNA helicases, mRNA cap guanine-N7 
methyltransferase, RNMT, RAE1) supporting its function 
in translation (Additional file 3: Table S1).
Network analysis of hnRNPD protein interactions
Ingenuity pathway analysis (IPA) was carried out to gen-
erate the network of proteins identified in the hnRNPD 
interactome analysis. The criteria applied for the search 
of major biological function categories were maximum 
number of proteins and a significant p value. Our net-
work analysis revealed novel signaling proteins that may 
interact (directly/indirectly) with hnRNPD and/or regu-
late its associated networks (Fig. 2) in addition to the pro-
teins identified in our proteomics analysis. IPA analysis 
revealed 90 canonical signaling pathways significantly 
Fig. 2 IPA analysis based hnRNPD networks in oral cancer. Network analysis obtained using Ingenuity Pathway Analysis (IPA) demonstrating 
interactions (direct/indirect) of hnRNPD with proteins involved in cellular signaling pathways including mTOR and eNOS; Double strand DNA repair 
mechanism (XRCC5, XRCC6); Chromatin remodeling (SMARCC1, SMARCC2, SMARCB1, SMARCD1, SMARCD2, SMARCE1 and histone family of pro-
teins including H1, H2A, H2B and H4); Telomere maintenance (hnRNPA2/B1, XRCC5, XRCC6, hnRNPA1); RISC (short-interfering-RNA-mediated gene 
silencing) (EIF2C1, EIF2C2, EIF2C3), RNA splicing, stability, translation and decay (ribosomal proteins 28S, 40S and 60S; ATP dependent RNA helicases, 
mRNA cap guanine-N7 methyltransferase, RNMT, RAE1, PTBP1, FIP1L1, DHX15, RSL1D1, RBMS1, RBM12B)
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associated with hnRNPD (p-value <0.001, Additional 
file 3: Table S2). The binding partners of hnRNPD identi-
fied herein were also classified on the basis of their cellu-
lar functions (Additional file 3: Figure S1B). Cleavage and 
polyadenylation of pre-mRNA, nucleotide excision repair 
pathway, EIF2 signaling, mammalian target of rapamycin 
(mTOR) signaling, regulation of eukaryotic initiation fac-
tor 4 (eIF4) and p70S6K signaling, nitric oxide synthase 
(NOS), and estrogen receptor signaling emerged as sig-
nificant pathways associated with hnRNPD (Fig. 2; Addi-
tional file 3: Table S2).
Verification of interactions between hnRNPD and 14‑3‑3ζ, 
hnRNPK and S100A9
As a first step for verification of interactions between 
hnRNPD and 14-3-3ζ observed in proteomics analysis, 
we performed motif scan (14-3-3—Mode 1/Mode 2) 
using software available online at http://www.motifscan.
mit.edu as described earlier [26]. Motif search showed 
the presence of 14-3-3 binding motif Mode1 (EDEGH-
SNSSPRHSEA) in hnRNPD protein (Fig.  3A, i). Co-
immunoprecipitation assays followed by western blot 
analysis were performed for both hnRNPD and 14-3-3ζ 
protein to verify their direct interactions in oral cancer 
cells (SCC4/MDA1986). As shown in Fig.  3A, 14-3-3ζ 
was detected in immunocomplexes of hnRNPD obtained 
from SCC4 and MDA1986 cells. Similarly, using reverse-
IP experiments, hnRNPD was detected in immunocom-
plexes of 14-3-3ζ obtained from both the oral cancer cell 
lines (SCC4/MDA1986), while no band was detected in 
negative controls (Fig. 3A, ii). This interaction was further 
evident by co-localization of both these proteins in oral 
cancer cells (Fig.  3A, iii). Further, co-IP assays followed 
by western blotting using phospho-specific hnRNPD 
(83Ser) antibody showed the presence of 14-3-3ζ in both 
the oral cancer cell lines (SCC4 and MDA1986, Fig. 3A, 
iv). In addition, our results also demonstrated presence of 
14-3-3ζ protein in hnRNPD immunocomplexes, obtained 
from OSCC tissue lysates (Fig. 3A, v).
Using similar approach, we verified the interaction 
of hnRNPD with hnRNPK and S100A9 in oral cancer 
cells. Western blotting showed presence of hnRNPK 
and S100A9 in hnRNPD immunoprecipitates and these 
findings were also confirmed using reverse—IP (Fig. 3B, 
i). Confocal laser scan microscopy (CLSM) analysis 
confirmed cytoplasmic and nuclear co-localization of 
hnRNPD with hnRNPK in OSCC cell lines, SCC4 and 
MDA1986 (Fig. 3B, ii).
Immunohistochemical analysis of hnRNPD expression 
in oral normal mucosa, dysplasia and OSCCs
Further, we performed immunohistochemistry to evalu-
ate the clinical relevance of hnRNPD overexpression in 
tissue specimens of oral dysplasia and OSCCs. We per-
formed immunohistochemistry of hnRNPD protein in 
oral normal mucosa (n  =  106), dysplasia (n  =  44) and 
OSCC (n = 183) tissues and analyzed its expression sep-
arately in both nucleus and cytoplasm of epithelial cells 
in each tissue section. The immunoreactivity score of 4 
was selected as the threshold of hnRNPD immune-posi-
tivity based on the high sensitivity and specificity (>75 %) 
obtained with this cut off score in ROC analysis. Notably, 
weak or no detectable nuclear hnRNPD immunostain-
ing was observed in 86/106 cases (81.1 %) normal tissues 
(Fig. 4a), while 20 cases only (18.9 %) showed moderate 
nuclear expression in epithelial cells of basal/supraba-
sal layer. Increased nuclear expression of hnRNPD was 
observed in 54.5 % dysplasia (24 of 44 cases, p < 0.001). 
Among different grades of dysplasia, 62.5  % of mild, 
33.3  % moderate and 33.3  % severe dysplasia showed 
overexpression of nuclear hnRNPD (Table 1, Fig. 4c). Of 
183 OSCCs analyzed in this study, 65.6 % cases showed 
increased nuclear hnRNPD expression in tumor cells as 
compared to normal oral mucosa (p < 0.001, odds ratio 
(OR)  =  8.1, 95  % CI  =  4.6–14.5; Table  1 and Fig.  4d). 
Overexpression of nuclear hnRNPD showed signifi-
cant correlation with increasing tumor size (p =  0.005, 
OR = 2.4, 95 % C.I. = 1.3–4.6) and tumor stage (p = 0.02, 
(See figure on next page.)
Fig. 3 Verification of hnRNPD binding partners in oral cancer. A, i 14-3-3 binding motif of hnRNPD. Photomicrograph showing presence of 14-3-3 
binding motif, Mode 1 in hnRNPD polypeptide sequence as revealed by http://www.motif.scan.mit.edu; ii Western blot showing presence of 14-3-3ζ 
and hnRNPD proteins in immunoprecipitates of hnRNPD/14-3-3ζ obtained from OSCC cells (SCC4 and MDA1986) while no band was seen in nega-
tive controls (i.e. beads only control). Input represents whole cell lysates from MDA1986 used as positive control for Western blotting; iii Confocal 
laser scan microscopy (CLSM) demonstrating nuclear and cytoplasmic expression of 14-3-3ζ (green, FITC) and hnRNPD (red, TRITC) in oral cancer cells 
a SCC4 and b MDA1986 cells. Blue colored DAPI was used as nuclear stain. Merged photomicrographs represent the co-localization of hnRNPD with 
14-3-3ζ in oral cancer cells; iv Confirmation of binding of 14-3-3ζ at p-Ser83 of hnRNPD in oral cancer cells. Western blot revealed the presence of 
p-Ser83 of hnRNPD in immunoprecipitates obtained by using anti-14-3-3ζ antibody from SCC4 and MDA1986 cell line; B Western blot showing pres-
ence of hnRNPK and S100A9 proteins in immunoprecipitates of hnRNPD obtained from OSCC cells (SCC4 and MDA1986) while no band was seen in 
negative controls. Input represents whole cell lysates from MDA1986 used as positive controls; ii Confocal laser scan microscopy (CLSM) demon-
strating nuclear and cytoplasmic expression of hnRNPK (green, FITC) and hnRNPD (red, TRITC) in oral cancer cells a SCC4 and b MDA1986 cells. Blue 
colored DAPI was used as nuclear stain. Merged photomicrographs represent the co-localization of hnRNPD with hnRNPK in oral cancer cells
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OR = 2.3, 95 % C.I. = 1.0–5.2, Table 1). Thirteen of 183 
(7.1  %) OSCCs showed cytoplasmic immunostaining 
of hnRNPD (Fig.  4d), but no significant association of 
cytoplasmic hnRNPD was observed (data not shown). 
Lung cancer tissue sections used as positive controls 
showed strong nuclear hnRNPD expression (Fig.  4e), 
Fig. 4 Immunohistochemical analysis of hnRNPD in oral tissues. Paraffin-embedded sections of histologically normal mucosa, oral dysplasia and 
OSCC were stained using anti-hnRNPD polyclonal antibody as described in “Methods” section. Panel represents a normal oral mucosa showing no 
hnRNPD immunostaining; b Dysplasia section illustrating nuclear hnRNPD staining in epithelial cells; c OSCC section illustrating nuclear hnRNPD 
staining in tumor cells; d OSCC section illustrating nuclear (N) and cytoplasmic (C) hnRNPD staining in tumor cells; e Lung cancer tissue section 
showing nuclear hnRNPD immunostaining; f OSCC section used as a negative control, showing no hnRNPD immunostaining in tumor cells; (a–e 
original magnification ×200)
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while no immunostaining was observed in tissue sections 
used as negative controls where the primary antibody 
was replaced by isotype specific IgG (Fig. 4f ). No signifi-
cant alterations were observed in cytoplasmic hnRNPD 
expression in these tissues (data not shown).
Evaluation of nuclear hnRNPD overexpression as a 
prognostic marker for OSCC
We determined association of nuclear hnRNPD with 
survival of OSCCs using Kaplan–Meier (KM) analysis 
followed by multivariate Cox regression analysis. Kaplan–
Meier survival analysis showed significantly reduced 
recurrence-free survival (median RFS  =  15  months, 
p  =  0.013) in OSCC patients harboring increased 
nuclear hnRNPD expression as compared to median 
RFS of 69 months in patients showing no or low nuclear 
hnRNPD (Fig. 5a). Notably, among OSCC patients with 
negative nodal status (i.e. N0) hnRNPD nuclear expres-
sion emerged as a significant predictor for recurrence 
with median RFS = 22 months as compared to patients 
who were negative for histopathological involvement 
of nodes and showed low score on nuclear hnRNPD 
(median RFS =  69.0  months, p =  0.028, Fig.  5b). How-
ever, nuclear hnRNPD did not show any significant 
association with recurrence among OSCC patients with 
positive nodes at time of surgery (p = 0.141).
Cox regression multivariate analysis was carried out to 
determine the prognostic potential of nuclear hnRNPD 
for OSCCs in comparison with the other clinical param-
eters including age, gender, histological grade, tumor 
Table 1 Analysis of hnRNPD protein expression and correlation with clinicopathological parameters
* Tobacco consumption habits include tobacco chewing and/or smoking of bidi or cigarettes, chewing of betel quid, areca nut or pan masala
a Normal vs. dysplasia
b Normal vs. OSCCs
Clinicopathological features Total cases
N
Nuclear n Positivity (%) p value Odd’s ratio (95 % CI)
Normal 106 20 (18.9)
Dysplasia 44 24 (54.5) <0.001a 5.4 (2.5–11.7)
 Mild 31 18 (58.0)
 Moderate 10 4 (40)
 Severe 3 1 (33.3)
OSCCs 183 120 (65.6) <0.001b 8.1 (4.6–14.5)
Age (median 45 years)
(range 15–85 years)
 <45 64 47 (73.4)
 ≥45 119 73 (61.3) 0.10 0.5 (0.2–1.1)
Gender
 Male 149 102 (68.5)
 Female 34 18 (52.9) 0.08 1.9 (0.9–4.1)
Differentiation
 WDSCC 89 57 (64.0)
 MDSCC 86 58 (67.4)
 PDSCC 8 5 (62.5) 0.87 –
Tumor size
 T1 + T2 65 34 (52.3)
 T3 + T4 118 86 (72.9) 0.005 2.4 (1.3–4.6)
Tumor stage
 I + II 31 15 (48.4)
 III + IV 152 105 (69.1) 0.02 2.3 (1.0–5.2)
Nodal status
 N0 61 37 (60.7)
 N1–4 122 83 (68.0) 0.32 1.3 (0.7–2.6)
Habits*
 Non consumer 33 27 (69.7)
 Tobacco consumer 150 97 (64.7) 0.58 0.7 (0.3–1.7)
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size, nodal status and stage (Table  2). Nuclear hnRNPD 
emerged as the most significant marker for predicting 
recurrence in OSCC patients [p  =  0.026, Hazard ratio 
(HR) = 1.95, 95 % CI = 1.0–3.5].
Further, ROC analysis showed an area under the curve 
(AUC) of 0.725 and 0.782 for dysplasia and OSCCs 
respectively for nuclear hnRNPD overexpression with 
high specificity, implicating its potential utility in distin-
guishing these tissues from normal epithelium (Table 3, 
Fig.  5c). Sensitivity, positive predictive value (PPV) and 
negative predictive value (NPV) for distinguishing dys-
plasia and OSCCs from normal oral mucosa are given in 
Table 3.
hnRNPD overexpression correlates with 14‑3‑3ζ 
and hnRNPK expression in OSCCs tissues
As shown above, both hnRNPK and 14-3-3ζ were iden-
tified in as interaction partners of hnRNPD in oral 
cancer cells and tissues. On the basis of IHC analysis, 
the immunoreactivity score ≥4 for both hnRNPD and 
Fig. 5 Evaluation of hnRNPD overexpression as a prognostic marker for OSCC. a Evaluation of nuclear hnRNPD as a prognostic marker. Based on 
sensitivity and specificity values a cut-off ≥4 was defined as positive criterion for hnRNPD (nuclear). Kaplan–Meier estimation of recurrence-free sur-
vival (RFS; no recurrence/metastasis) in OSCC patients showing nuclear immunostaining of hnRNPD was 15 months as compared to 69 months for 
the patients showing low scores for nuclear hnRNPD immunostaining (p = 0.013). b Kaplan–Meier estimation of recurrence-free survival, in node 
negative OSCC patients showing nuclear immunostaining of hnRNPD was median RFS = 22 months as compared to 69 months for the patients 
showing low scores for nuclear hnRNPD immunostaining and absence of node (p = 0.028). c Evaluation of nuclear hnRNPD as a diagnostic marker 
for distinguishing oral dysplasia and OSCCs from normal oral tissues. Panel shows ROC analysis for i Oral dysplasia vs. normal and ii OSCCs vs. normal 
oral tissues
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hnRNPK, and a score ≥5 for 14-3-3ζ were considered 
as overexpression and were used in Kappa analysis. In 
order to confirm such association among clinical speci-
mens of OSCCs, we performed Kappa analysis to deter-
mine the agreement of association between the hnRNPD, 
hnRNPK and 14-3-3ζ expressions in OSCCs using their 
IHC scores. One of the most important features of 
the Kappa statistics is that it is a measurement of the 
degree of agreement or reliability of agreement. Among 
OSCCs, 61 % agreement with a Kappa score (κ = 0.236) 
was observed between nuclear hnRNPD and hnRNPK 
(p = 0.0003) (Additional file 3: Table S3). Similar agree-
ment with a Kappa score (κ = 0.248) was also observed 
between nuclear hnRNPD and 14-3-3ζ. This further 
strengthened our results of IP-LC–MS/MS. However, no 
significant agreement was observed between cytoplas-
mic expression of hnRNPD with hnRNPK or 14-3-3ζ in 
OSCCs.
Discussion
The ability of proteins to form complexes by physically 
binding to each other and alterations in sub-cellular dis-
tribution lead to perturbations in the cell circuitry under-
lying cancer development. In this study, we determined 
hnRNPD associated protein networks to get an insight in 
molecular pathogenesis of oral cancer. Our network anal-
ysis revealed involvement of hnRNPD in multiple cellular 
pathways involved in progression and metastasis of oral 
cancer. We identified novel binding partners of hnRNPD 
suggesting its involvement in DNA repair, chromatin 
remodeling, RNAi mediated gene silencing and several 
other cell signaling pathways involved in cellular prolif-
eration and apoptosis, besides its role in RNA process-
ing and turnover. Several reports have demonstrated 
involvement of different RNA-binding proteins (RBPs) 
in determining the cellular fate of mRNA transcripts 
in terms of stability and rate of translation [11, 22]. In 
this respect, we observed other members of the hnRNP 
family including hnRNPA2/B1, hnRNPK, hnRNPU, 
hnRNPG forming heterodimers with hnRNPD in oral 
cancer cells. In this support, interaction of hnRNPK, 
hnRNPC, hnRNPL and hnRNPA2/B1 with hnRNPD in 
cervical and lung cancer cells has been reported earlier 
[31–33]. In addition, our results also suggested interac-
tion of hnRNPD with other RNA binding proteins (RBPs) 
such as ELAVL1, RALY, EWSR1 and FUS in oral cancer. 
The fate of RNAs regulated by these protein interac-
tions among hnRNPD and other RNA binding proteins 
in oral cancer is currently under investigation. However, 
a recent study reported RNA—dependent direct physi-
cal interaction between ELAVL1 and hnRNPD in the 
nucleus influences the expression of cyclin D1 and p16, 
both of which are important for oral cancer development 
[34, 35]. Besides RBPs, microRNAs are also important 
contributors to the post-transcriptional control of gene 
expression [36]. miRNAs act preferentially by binding to 
3′-UTR region of target mRNA and are also involved in 
ARE-mediated mRNA instability. Precursor miRNAs are 
processed to mature miRNAs by multiprotein complexes 
including Drosha and Dicer and then incorporated into 
RNA induced silencing complex (RISC) [37]. We iden-
tified RNA polymerase II, eIF4 and argonaute proteins 
(EIF2C1, EIF2C2 and EIF2C3) that are important com-
ponents of RISC in our interactome analysis of hnRNPD 
in oral cancer. hnRNPD associates with endogenous 
DICER1 mRNA and destabilizes it; however knockdown 
of hnRNPD using siRNA increased half-life of DICER1 
mRNA and elevated its expression, while overexpression 
of hnRNPD lowered DICER1 mRNA and protein levels 
[38].
Interestingly, we also identified an important nuclear-
cytoplasmic shuttling protein, 14-3-3ζ, a member 
of 14-3-3 family of proteins, as a binding partner of 
hnRNPD and verified their interaction in oral cancer cells 
(SCC4/MDA1986). Moreover, both hnRNPD and 14-3-
3ζ co-localization was observed in cytoplasm of OSCC 
cells, suggesting 14-3-3ζ retains cytoplasmic hnRNPD, 
similar to 14-3-3σ. 14-3-3 family of proteins is known for 
their overlapping functions in orchestrating their target 
proteins in cytoplasm. Our results also showed pres-
ence of 14-3-3 binding motif in hnRNPD polypeptide 
and verified the interaction of 14-3-3ζ with hnRNPD may 
be dependent on Ser83 phosphorylation (present in this 
Table 2 Evaluation of  nuclear hnRNPD as  a prognostic 
marker of OSCCs
Italicized value correspond to hnRNPD which immerged as an independent 
prognostic marker OSCC
a Cox multivariate analysis: Hazard ratio (HR) 1.95, 95 % CI 1.0–3.5
S. no. Clinicopathological parameter p value
1 Histopathologic grade 0.233
2 Tumor size 0.504
3 Tumor stage 0.340
4 Nodal status 0.359
5 hnRNPD (nuclear) 0.026a
6 Tobacco habits 0.709
7 Gender 0.439
8 Age 0.050
Table 3 Evaluation of hnRNPD as a diagnostic marker
hnRNPD Specificity Sensitivity PPV NPV AUC
Dysplasia vs. normal 81.1 54.5 81.0 56.0 0.723
OSCCs vs. normal 81.1 65.5 86.0 58.0 0.782
Page 13 of 15Kumar et al. J Transl Med  (2015) 13:285 
motif ), unlike its interaction with 14-3-3σ, as reported 
earlier [39, 40]. Previous reports have shown binding of 
14-3-3σ to hnRNPD masks its nuclear localization sig-
nal, retaining it in cytoplasm and enhances the rapid 
turnover of its target protein expression [39, 40]. Further, 
hnRNPD demonstrated significant association with 14-3-
3ζ expression in clinical specimens of OSCCs analyzed in 
this study. In thyroid cancer, cytoplasmic hnRNPD inter-
acts with mRNAs encoding cyclins (A1, B1, D1 and E1) 
and cyclin-dependent kinase inhibitors [41]. Stimulation 
of melanoma cells and monocytes by lipopolysaccharide 
resulted in cytoplasmic translocation of hnRNPD from 
nucleus and reduced levels of IL-6, IL-10 and TNF-α 
following activation of MKP-1 (MAPK phosphatase-1) 
[42–47]. This scenario might explain how nuclear-cyto-
plasmic translocation of hnRNPD can influence the cyto-
plasmic fate of mRNA.
Together, our network analysis suggested an important 
role of hnRNPD overexpression and its associated net-
works including protein interactions (direct/indirect) and 
regulation among these pathways is likely to play impor-
tant role in determining the clinical outcome of OSCC 
patients. Supporting this hypothesis, our clinical findings 
demonstrated increased nuclear hnRNPD expression in 
clinical specimens of oral dysplasia and OSCCs as com-
pared to normal oral mucosa. Notably, OSCC patients 
showing increased expression of nuclear hnRNPD had 
significantly reduced recurrence free survival. Nuclear 
hnRNPD overexpression in OSCCs and its emergence 
as a predictor of recurrence free survival in multivari-
ate analysis in comparison with clinical and pathological 
parameters is an important novel finding in oral cancer, 
even though previous studies reported its overexpres-
sion in other malignancies including thyroid, melanoma, 
breast, cervix and murine lung tumors [4, 7, 16, 18, 48, 49, 
35]. hnRNPD nuclear expression emerged as a significant 
predictor for recurrence with median RFS of 22 months 
as compared to patients who were node negative and 
had lower nuclear hnRNPD (median RFS = 69.0 months, 
p = 0.028). However, nuclear hnRNPD did not show any 
significant association with recurrence among OSCC 
patients with positive nodes at time of surgery. Thus, 
hnRNPD expression is likely to have the potential to 
define a high-risk subgroup among OSCC patients with 
nodal negative disease and might address the urgent need 
for more effective risk stratification strategies to improve 
patient care for these patients.
Conclusions
Our interactome analysis of hnRNPD protein provided 
an insight into its novel functions in oral cancer cells. 
Further, nuclear hnRNPD emerged as a prognostic 
marker for evaluating the risk of recurrence in OSCC 
patients. Based on these results, we suggest nuclear 
hnRNPD as a potential target for molecular therapeutics 
for oral cancer in future.
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